These summary minutes for the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee were approved on ___3/7/05____.
I certify that I attended the February 16, 17 and 18, 2005, Joint meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration and that these minutes accurately reflect what transpired.
________//S//_________________ ________//S//____________________
LCDR Dornette Spell-LeSane, MHA, NP-C Alastair
Wood, M.D.
Supervisory Health Science Administrator Chair
For, Kimberly Topper, M.S.,
Executive Secretary
Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk
Management Advisory Committee
The
following is an internal report, which has not been reviewed. It is not meant
to be a comprehensive review of the meeting.
A verbatim transcript will be available in
approximately two weeks, sent to the Division and posted on the FDA website at http://www.fda.gov/ohrms/dockets/ac/cder05.html#ArthritisDrugs. Slides shown at
the meeting will be available at the same website.
All external requests for the meeting minutes and transcripts should be submitted to the CDER Freedom of Information office.
_____________________________________________________________________
Arthritis Advisory Committee Members
Present (voting):
Joan Bathon, M.D.,
Dennis Boulware, M.D., John J. Cush, M.D., Michael Finley, D.O.,
Allan Gibofsky,
M.D., Gary Hoffman, M.D., Norman Ilowite, M.D., Susan Manzi, M. M.D.,
M.P.H.
Drug Safety and Risk Management Advisory
Committee Members Present (voting):
Stephanie Y.
Crawford, Ph.D., Ruth S. Day, Ph.D.,
Jacqueline S.Gardner,
Ph.D., MPH, Peter A. Gross, M.D., Eric S. Holmboe, M.D.
Arthur A. Levin, M.P.H., Louis
A. Morris, Ph.D., Richard Platt, M.D.,
M.Sc,
Robyn S. Shapiro, J.D., Annette
Stemhagen, Dr.Ph
SGE Consultants (voting):
Robert H. Dworkin,
Ph.D., Steven Nissen, M.D.,
Emile Paganini,
M.D., Leona Malone, L.C.S.W., (Patient Rep) , Thomas Fleming, Ph.D.,
John T. Farrar,M.D., Janet Elashoff, Ph.D., Ralph D’Agostino, Ph.D.
SGE
Consultants (non voting):
Cryer, Byron, M.D.,
(Speaker and Discussant) Packer, Milton M.D., (Speaker only)
National
Richard O. Cannon III, M.D., Michael J. Domanski, M.D., Lawrence Friedman, M.D.
FDA Invited Guest
Speakers (non-voting):
FDA Participants
at the Table:
Jonca Bull, M.D., Brian Harvey, M.D.,
John Jenkins, M.D., Sandra Kweder, M.D., Robert O'Neil, Ph.D., Paul
Seligman, M.D., Steve Galson, M.D., Robert Temple, M.D., Anne Trontell, M.D.,
M.P.H.
FDA
Presentors:
David Graham, M.D.,
M.P.H., Sharon Hertz, M.D., Joel
Schiffenbauer, M.D.,
Lourdes
Villalba, M.D., James Witter, M.D.
Open Public
Hearing Speakers:
Joan Brierton Johnson and Sabrina |
|
Sidney M. Wolfe, MD |
Director,
Public Citizen's Health Research Group |
Linda Suydam |
Vice President,
Regulatory and Scientific Affairs, Consumer Healthcare Products Association -
CHPA |
Jennifer Lo, Ph.D. and Gene Luther, D.V.M., Ph.D. |
CEO &
President, BioJENC, LLC, |
Jim Tozzi |
Member,
Board of Advisors, Center for
Regulatory Effectiveness |
Diana Zuckerman, Ph.D. |
President,
|
Elizabeth Tindall, MD |
President, |
Dimitra Poulos |
|
John Pippin, M.D. |
Physicians Coomittee for Responsible Medicine |
MAJ Christopher Grubb, M.D. |
|
Janet Arrowsmith-Lowe, MD |
President,
Arrowsmith-Lowe Consulting, Inc. |
Mark H. Einstein,
M.D. |
Assistant
Professor, Division of Gynecologic Oncology, Department of Obstetrics &
Gynecology and Women's |
John Abramson M.D. |
|
Herbert S. B. Baraf, MD, FACP, FACR |
Clinical
Professor of Medicine, |
Max Hamburger MD |
|
|
Associate
Professor of Medicine, Chief of Endoscopy, |
David P. Matthews |
|
W. |
Chief
of Rheumatology, |
Gary W. Williams, M.D.,
Ph.D. |
Chairman, Department of Medicine and Vice President of Medicine
Services, at Scripps Clinic and Research Foundation |
Rebecca Burkholder |
Director
of Health Policy, National Consumers League |
Amye L. Leong, MBA |
President & CEO, Healthy Motivation, Spokesperson,
UN-endorsed Bone and Joint decade 2000-2010 |
Donna Marie Fox- Keidel |
|
Theresa Ray |
|
Judith Whitmire |
|
Judy Fogel |
Brigham
& Women's Hospital, |
R. |
Brigham
& Women's Hospital, |
|
Adjunct
Clinical Professor of Medicine |
Dr. Allan N. Fields |
|
Grant Johnson |
|
Necole Kelly |
President,
American Chronic Pain Association |
Robert Thibadeau, Ph.D. |
|
|
Assistant
Professor of Medicine, Department of Gastroenterology, Uniformed |
Susan Winckler, RPh, Esq., |
APhA’s
Vice President of Policy and Communications and Staff Counsel |
Virginia Ladd |
President
American Autoimmune Related Diseases Association (AARDA) |
Paola Patrignani, Ph.D. |
Professor
of Pharmacology, Department of Medicine and |
Betsy Chaney |
|
Dr. John
Klippel |
President
and CEO of the Arthritis Foundation |
Carol Spitz |
|
Eileen Lacijan |
|
Gloria Barthelmes |
|
Rebecca Dachman |
|
Michael D. Paranzino |
President,
Psoriasis Cure Now! |
Dr. Glenn Eisen |
|
Yvonne Sherrer, M.D. |
|
___________________________________________________________________
The members and the invited
consultants were provided with the background material from the FDA, Merck,
Pfizer, Novartis, Hoffmann-La Roche Inc., and Bayer Healthcare LLC, Consumer
Care Division prior to the meeting.
The meeting was called to
order at
Call to Order Alastair J. J. Wood, M.D., Chair
Conflict of Interest Statement Kimberly Littleton Topper, M.S.
Executive Secretary
Welcome Steven Galson, M.D., M.P.H.
Acting Director, Center for Drug
Evaluation and Research (CDER)
Regulatory History Jonca Bull, M.D.
Director, Office of Drug
Evaluation V,
CDER
Gastrointestinal Effects of NSAIDs and Byron Cryer, M.D.
COX-2 Specific Inhibitors
Southwestern
Mechanism Based Adverse Cardiovascular
Events and Specific Inhibitors of COX-2
Committee Questions to Speakers
Break
Vioxx (rofecoxib)
Sponsor Presentation:
Rofecoxib Ned
S. Braunstein, M.D.
Senior Director
Merck Research Laboratories
FDA Presentation:
Vioxx Lourdes
Villalba, M.D.
Cardiovascular Safety Medical Officer, CDER
Committee Questions to Speakers
Lunch
Celebrex (celecoxib)
Sponsor
Presentation:
Introduction Joseph M. Feczko, M.D.
Senior Vice President,
Pfizer Global Research and Development, and President, Worldwide Development
Cardiovascular Safety and Kenneth M. Verburg, Ph.D.
Risk/Benefit Assessment of Celecoxib Vice President, Inflammation and
Immunology, Clinical Research and Development, Pfizer Global Research and Development
FDA Presentation:
COX-2 CV Safety: celecoxib James
Witter, M.D., Ph.D.
Lead Medical Officer, CDER
NIH and Investigator Presentation:
Celecoxib in Adenoma Prevention Trials:
The APC Trial Ernest
Hawk, M.D., MPH
(Prevention of Sporadic Colorectal Director,
Office of Centers,
Adenomas with Celecoxib) Training,
& Resources
NCI/OD/NIH
The PreSAP Trial Bernard Levin, M.D
(Prevention of
Colorectal Sporadic
Adenomatous Polyps) The
Committee Questions to Speakers
Break
Sponsor Presentation:
Cardiovascular Safety and Risk/Benefit Kenneth M. Verburg, Ph.D.
Assessment of Valdecoxib and Parecoxib
Closing Joseph M. Feczko, M.D.
FDA Presentation:
COX-2 CV Safety: valdecoxib – parecoxib James Witter, M.D., Ph.D.
Sponsor Presentation:
Bayer and Roche Joint Presentation on Naproxen Leonard M. Baum, R.Ph.
Vice President, Regulatory Affairs
Bayer HealthCare
Consumer Care Division
Martin H. Huber, M.D.
Vice President, Global Head
Drug Safety Risk Management,
Hoffmann-La Roche, Inc.
Committee Questions to Speakers
Call to Order Alastair J. J. Wood, M.D., Chair
Conflict of Interest Statement Kimberly Littleton Topper, M.S.
Interpretation of Observational Studies of Richard Platt, M.D., M.S.
Cardiovascular Risk of Non-steroidal Drugs
Review of Epidemiologic Studies on David Graham, M.D., M.P.H.
Cardiovascular Risk with Selected NSAIDs Medical Officer, CDER
Committee Questions to Speakers
Arcoxia (etoricoxib)
Sponsor Presentation:
Etoricoxib Sean P. Curtis, M.D.
Senior Director, Clinical Research
Merck Research Laboratories
FDA Presentation:
Analysis of Cardiovascular Thromboembolic Joel Schiffenbauer, M.D.
Events With Etoricoxib Medical Officer, CDER
Break
Lumiracoxib
Sponsor Presentation:
Lumiracoxib: Introduction Mathias Hukkelhoven, Ph.D.
Senior Vice President and Global
Head, Drug Regulatory Affairs
Novartis Pharmaceuticals Corporation
Gastrointestinal and Cardiovascular Safety Patrice Matchaba, M.D.
of Lumiracoxib, Ibuprofen, and Naproxen Global Medical Director
Lumiracoxib Program, Novartis Pharmaceuticals Corporation
FDA
Presentation:
Lumiracoxib Lourdes
Villalba, M.D.
Medical Officer, CDER
Committee Questions to Speakers
Lunch
Open Public Hearing
Break
Committee Discussion
Call to Order Alastair J. J. Wood, M.D.,Chair
Conflict of Interest Statement Kimberly Littleton Topper, M.S.
Naproxen
Investigator Presentation:
Alzheimer’s Prevention Study : ADAPT Constantine Lyketsos, M.D.
(Alzheimer’s Disease Anti-Inflammatory The John Hopkins Hospital
Prevention Trial)
Additional Background Presentations
Interpretation of Observed Differences Milton Packer, M.D.
in the Frequency of Events When the
Number of Events is
Small Southwestern
Medical School
Committee Questions to Speakers
Clinical Trial Design and Patient Safety: Robert Temple, M.D.
Future Directions for COX-2 selective NSAIDs Director, Office of Medical
Policy, CDER
Issues in Projecting Increased Risk of Robert O’Neill, Ph.D.
Cardiovascular Events to the Exposed Population Director, Office of Biostatistics, CDER
Committee Questions to Speakers
Break
Risk Management Options for Action Anne Trontell, M.D.,
M.P.H.
(added to agenda on
Summary of Meeting Presentations Sharon Hertz, M.D.
Deputy Director, Division of
Anti-Inflammatory, Analgesic and Ophthalmologic Drug Products, CDER
Advisory Committee Discussion of Questions
Lunch
Advisory Committee Discussion of Questions
Break
Advisory Committee Discussion of Questions
Meeting Wrap-up Alastair J. J. Wood, M.D.
Adjourn
Discussion Points:
1. Please discuss the available data regarding the potential cardiovascular (CV) risk for the non-selective and COX-2 selective NSAIDs. Please discuss whether the available data support a conclusion that increased CV risk is a class effect for all NSAIDs, the COX-2 selective NSAIDs only, or only for certain agents within the class. Also, please discuss the possible mechanism(s) of action for an increased cardiovascular risk with these agents.
The Committee shared various opinions with the members agreeing, in
general, that there was inadequate data to draw a definite conclusion regarding
whether a class effect exists. However, that being said, they agreed that it
did appear likely that for at least the three approved COX-2 products, a class
effect appears to be present. They
further indicated that they believed that if sufficient drug was given in high
enough doses to high risk patients an increase incidence of cardiovascular
events would be yielded. There is a
dearth of data on the other NSAIDs and the consensus of the Committee was that
each drug should be individually evaluated for CV risk. It is unknown whether a CV signal is present
across all the products, with possible different mechanisms of action, but each
is suspect when used chronically and until proven otherwise,
patients/physicians should be warned.
2.
Please discuss the contributions and
limitations of the currently available observational studies to the assessment
of CV risk for the non-selective and COX-2 selective NSAIDs. In particular, please discuss the role of
such observational studies in informing regulatory decisions about
post-marketing safety issues.
While the Committee stated various opinions, most agreed that observational studies do provide useful, although limited, information. In general, observational studies are supplementary to randomized, controlled, clinical trials (RCT) since selection bias is likely present. Additional comments provided by the committee were:
3. Please discuss the available data regarding the potential benefits of COX-2 selective NSAIDs versus non-selective NSAIDs and how any such benefits should be weighed in assessing the potential benefits versus the potential risks of COX-2 selective agents from a regulatory perspective.
Overall the committee felt that the GI benefits should not be
minimized, however, the GI benefits of the COX-2s appear to be less than first
reported. Vioxx is the only product with
GI benefit in labeling; no clear data that show GI benefit for Celebrex and
Bextra. Although not a benign event, a GI event is in most cases not as
permanently disabling as a myocardial infarction or a stroke. The Committee
members offered the following additional considerations for weighing benefit
versus risk:
·
Pediatric issues should be considered; there are fewer choices in this population
and only 3 NSAIDs are approved for use in pediatric population, only 2 liquid
formulations
·
Tolerability - fewer serious GI events, but
a lot of symptoms should be considered
Questions to the
Committee
Approved products
Three COX-2 selective NSAIDs are currently approved for
marketing in the
Although Merck voluntarily withdrew Vioxx from marketing
worldwide on
Based on the data presented in the background package and during the committee meeting, please address the following questions regarding the approved COX-2 selective NSAIDS.
1. Celecoxib
a. Do the available data support a conclusion that celecoxib significantly increases the risk of cardiovascular events?
Yes- 32 No- 0 Abstain
- 0
b.
Does the
overall risk versus benefit profile for celecoxib support marketing in the
Yes - 31 No
- 1 Abstain
- 0
c. If yes, please describe the patient population(s) in which the potential benefits of celecoxib outweigh the potential risks and what actions you recommend that FDA consider implementing to ensure safe use of celecoxib.
·
The Committee agreed that osteoarthritis and
rheumatoid arthritis patients, in addition to patients being treated for pain
were populations where the benefits of celecoxib could outweigh potential
risks. They agreed that there appeared
to be no evidence of CV risk at the 200 mg dose and marginally positive
evidence at the 400 mg dose. No signal
was seen in the epidemiologic studies.
With regard to the colon polyp study, 400 and 800 mg doses were
studied. An excess CV risk would likely
be seen with the 800 mg dose, probable at the 400 mg dose and possibly no
evidence with the 200 mg dose.
The following were suggested as
potential actions for the FDA to take:
practitioners (22)
2. Valdecoxib
a. Do the available data support a conclusion that valdecoxib significantly increases the risk of cardiovascular events?
Yes - 32 No – 0 Abstain - 0
b.
Does the overall risk versus benefit profile for
valdecoxib support marketing in the
Yes - 17 No
- 13 Abstain - 2
c. If yes, please describe the patient population(s) in which the potential benefits of valdecoxib outweigh the potential risks and what actions you recommend that FDA consider implementing to ensure safe use of valdecoxib.
In general, the Committee felt that the evidence was very limited and
it is difficult to extrapolate to a real life setting.
The following were suggested as potential actions for the FDA to take.
3. Rofecoxib
a. Do the available data support a conclusion that rofecoxib significantly increases the risk of cardiovascular events?
Yes - 32 No - 0
Abstain - 0
b.
Does the overall risk versus benefit profile for
rofecoxib support marketing in the
Yes - 17 No - 15 Abstain - 0
The
Committee had the following comments:
·
The blood pressure effects seen with the
product are clearly outside the norm and are undesirable; a mechanism other
than a prostacyclin mechanism could be at play since the other COX-2s do not
appear to have such a large blood pressure effect
·
A signal for heart failure is present and
the other NSAIDs have not exhibited this same signal
·
The blood pressure and the heart failure
data is compelling indicating it is substantially worse than other COX-2s
·
A strong dose relationship is very apparent
·
Rofecoxib is the only COX-2 selective
product approved for pediatric patients however, there are minimal data to
support safe long-term use in pediatrics
c. If yes, please describe the patient population(s) in which the potential benefits of rofecoxib outweigh the potential risks and what actions you recommend that FDA consider implementing to ensure safe use of rofecoxib.
The following were suggested as potential actions for the FDA to take:
4. If the available data support a conclusion that one or more COX-2 selective agents increase the risk of cardiovascular events, please comment on the role, if any, of concomitant use of low-dose aspirin in reducing cardiovascular risk in patients treated with COX-2 selective NSAIDs.
No vote was offered for this question; some of the Committee comments
were as follows:
5. What additional clinical trials or observational studies, if any, do you recommend as essential to further evaluate the potential cardiovascular risk of celecoxib, rofecoxib, and valdecoxib? What additional clinical trials or observational studies, if any, do you recommend as essential to further evaluate the potential benefits (e.g., reduced gastrointestinal risk) of celecoxib, rofecoxib, and valdecoxib? Please be specific with regard to which COX-2 selective agent to study, trial design, patient populations, control groups, endpoints, duration, sample size, etc.
No vote was offered for this question; some of the Committee comments
were as follows:
·
Across all products and to rule out the risk
of excess cardiovascular events, additional randomized clinical trials (RCT)
should be conducted at doses to be marketed; blood pressure measurements should
be included in these trials
· Comparator drug used in the trials should not be limited to naproxen; placebo as the comparator should be used in trials designed to determine the absolute risk of CV events
There are more than 20 non-selective NSAIDs currently
approved for marketing in the
6. Do you recommend that the labeling for these products include information regarding the absence of long-term controlled clinical trial data to assess the potential cardiovascular effects of these drugs? If so, please describe how you recommend that information be conveyed (e.g., warning, precaution).
Yes - 28 No – 0 Abstain
- 0
(The following members were not present and therefore did not did not offer a vote for question 6: Paganini, Shapiro, Gibofsky, Hoffman)
Committee comments included:
7. What additional clinical trials or observational studies, if any, do you recommend as essential to further evaluate the potential cardiovascular risk of the non-selective NSAIDs? Please be specific with regard to which non-selective NSAIDs (i.e., all or only selected agents), trial design, patient populations, control groups, endpoints, duration, sample size, study drug etc.
The Committee comments
included:
Standards for
approval of new NSAIDs (non-selective and COX-2 selective agents)
The information that has accumulated about the safety and effectiveness of COX-2 selective NSAIDs since their approval, including the potential for increased cardiovascular risk, must be considered as FDA determines the standards for data to be submitted in support of approval of new non-selective and COX-2 selective NSAIDs. In addition, the experience with the approved COX-2 selective agents will help inform benefit versus risk assessments that will need to be made by FDA in evaluating pending and future applications for new NSAIDs.
Based on the data presented in the background package and during the committee meeting, please address the following questions regarding the approval of new non-selective and COX-2 selective NSAIDs.
8. With regard to evaluation of cardiovascular risk, what studies do you recommend as essential to be completed and reviewed prior to approval of new NSAIDs? With regard to the evaluation of the potential benefits (e.g., reduced gastrointestinal risk), what studies do you recommend as essential to be completed and reviewed prior to approval of new NSAIDs? Please be specific with regard to trial design, patient population, control groups, endpoints, duration, sample size, safety monitoring and patient protections, etc.
9. If the pre-approval studies recommended as essential in question 8 do not demonstrate an increased risk of cardiovascular events for a new NSAID, please comment on how FDA should handle the issue of cardiovascular risk in labeling. For example, would the absence of a cardiovascular risk signal in the pre-approval database preclude the need for any warnings or precautions in the labeling for the new product? Alternatively, should all future NSAIDs carry a “class” warning or precaution about cardiovascular risk even in the absence of a signal of increased risk in the pre-approval database? If yes, please describe your recommendations for the “class” labeling regarding cardiovascular risk with particular attention to whether you recommend it apply to all NSAIDs or only COX-2 selective NSAIDs.
No vote was offered for this question; The Committee made the following
comments:
·
The absence of establishing an increase risk
is not the same as no increase; evidence sufficiently powered and controlled to
rule out an increase in incidence is
needed
·
The Committee consensus was that for new
products, the standard for demonstrating safety should be higher
The meeting was adjourned at